太龍藥業(600222.SH):擬出資5000萬元在雲南設立全資子公司太龍本草
格隆匯1月19日丨太龍藥業(600222.SH)公佈,根據公司的戰略佈局,公司擬以貨幣資金出資人民幣5000萬元,在雲南設立全資子公司太龍本草。
投資標的名稱:雲南太龍本草資源開發有限公司(暫定名,最終以市場監督管理局核准的名稱為準);
經營範圍:中藥材、植物提取;便攜式電子霧化器研發與銷售;化粧品生產、銷售;保健品生產、銷售;食品生產、銷售;消毒劑生產(不含危險化學品)、銷售;醫療器械生產、銷售;技術服務、技術開發、技術諮詢、技術轉讓、技術推廣;農副產品銷售;互聯網銷售(除銷售需要許可的商品);技術進出口;貨物進出口。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.